Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Muley

Showing results (171-180 of 224) with videos related to

Pageof 23
Sort By:
International Journal of Cancer|March 19, 2015
Non-small cell lung cancer is characterized by dramatic changes in phospholipid profilesEyra Marien, Michael Meister, Thomas Muley, et al.
Lung Cancer (Amsterdam, Netherlands)|April 10, 2012
The gefitinib long-term responder (LTR)--a cancer stem-like cell story? Insights from molecular analyses of German long-term responders treated in the IRESSA expanded access program (EAP)Sandra Gottschling, Esther Herpel, Wilfried E E Eberhardt, et al.
Frontiers in Oncology|December 18, 2020
Consolidation Immunotherapy After Platinum-Based Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer-Cross-Sectional Study of Eligibility and Administration RatesTanja Eichkorn, Farastuk Bozorgmehr, Sebastian Regnery, et al.
Cancers|September 7, 2019
Clinical Significance of <i>SERPINA1</i> Gene and Its Encoded Alpha1-antitrypsin Protein in NSCLCEvrim Ercetin, Sarah Richtmann, Beatriz Martinez Delgado, et al.
Oncoimmunology|February 1, 2021
A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinomaJan Budczies, Martina Kirchner, Klaus Kluck, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2009
An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancerPaul Roepman, Jacek Jassem, Egbert F Smit, et al.
Cancers|September 24, 2020
Mass Spectrometry Imaging for Reliable and Fast Classification of Non-Small Cell Lung Cancer SubtypesMark Kriegsmann, Christiane Zgorzelski, Rita Casadonte, et al.
The European Respiratory Journal|December 28, 2020
An integrated multiomic and quantitative label-free microscopy-based approach to study pro-fibrotic signalling in <i>ex vivo</i> human precision-cut lung slicesMuzamil Majid Khan, Daniel Poeckel, Aliaksandr Halavatyi, et al.
American Journal of Respiratory and Critical Care Medicine|January 22, 2015
Hypoxic epithelial necrosis triggers neutrophilic inflammation via IL-1 receptor signaling in cystic fibrosis lung diseaseBenedikt Fritzsching, Zhe Zhou-Suckow, Joanna B Trojanek, et al.
International Journal of Cancer|January 25, 2018
EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK<sup>+</sup> non-small cell lung cancerPetros Christopoulos, Volker Endris, Farastuk Bozorgmehr, et al.
Pageof 23

Showing results (171-180 of 224) with videos related to

Sort By:
Pageof 23
International Journal of Cancer|March 19, 2015
Non-small cell lung cancer is characterized by dramatic changes in phospholipid profilesEyra Marien, Michael Meister, Thomas Muley, et al.
Lung Cancer (Amsterdam, Netherlands)|April 10, 2012
The gefitinib long-term responder (LTR)--a cancer stem-like cell story? Insights from molecular analyses of German long-term responders treated in the IRESSA expanded access program (EAP)Sandra Gottschling, Esther Herpel, Wilfried E E Eberhardt, et al.
Frontiers in Oncology|December 18, 2020
Consolidation Immunotherapy After Platinum-Based Chemoradiotherapy in Patients With Unresectable Stage III Non-Small Cell Lung Cancer-Cross-Sectional Study of Eligibility and Administration RatesTanja Eichkorn, Farastuk Bozorgmehr, Sebastian Regnery, et al.
Cancers|September 7, 2019
Clinical Significance of <i>SERPINA1</i> Gene and Its Encoded Alpha1-antitrypsin Protein in NSCLCEvrim Ercetin, Sarah Richtmann, Beatriz Martinez Delgado, et al.
Oncoimmunology|February 1, 2021
A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinomaJan Budczies, Martina Kirchner, Klaus Kluck, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2009
An immune response enriched 72-gene prognostic profile for early-stage non-small-cell lung cancerPaul Roepman, Jacek Jassem, Egbert F Smit, et al.
Cancers|September 24, 2020
Mass Spectrometry Imaging for Reliable and Fast Classification of Non-Small Cell Lung Cancer SubtypesMark Kriegsmann, Christiane Zgorzelski, Rita Casadonte, et al.
The European Respiratory Journal|December 28, 2020
An integrated multiomic and quantitative label-free microscopy-based approach to study pro-fibrotic signalling in <i>ex vivo</i> human precision-cut lung slicesMuzamil Majid Khan, Daniel Poeckel, Aliaksandr Halavatyi, et al.
American Journal of Respiratory and Critical Care Medicine|January 22, 2015
Hypoxic epithelial necrosis triggers neutrophilic inflammation via IL-1 receptor signaling in cystic fibrosis lung diseaseBenedikt Fritzsching, Zhe Zhou-Suckow, Joanna B Trojanek, et al.
International Journal of Cancer|January 25, 2018
EML4-ALK fusion variant V3 is a high-risk feature conferring accelerated metastatic spread, early treatment failure and worse overall survival in ALK<sup>+</sup> non-small cell lung cancerPetros Christopoulos, Volker Endris, Farastuk Bozorgmehr, et al.
Pageof 23